---
title: "Patria readies new private credit fund for Latin American deals- Bloomberg News"
description: "-- Source link: Note: Reuters has not verified this story and does not vouch for its accuracy"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275571228.md"
published_at: "2026-02-11T08:10:07.000Z"
---

# Patria readies new private credit fund for Latin American deals- Bloomberg News

> -- Source link: Note: Reuters has not verified this story and does not vouch for its accuracy

\-- Source link: https://tinyurl.com/mr33du6v

\-- Note: Reuters has not verified this story and does not vouch for its accuracy

### Related Stocks

- [PAX.US - Patria Investments](https://longbridge.com/en/quote/PAX.US.md)
- [PLAOF.US - PATRIA LATIN AM OPPORTUNI ACQ CORP](https://longbridge.com/en/quote/PLAOF.US.md)
- [PLAO.US - Patria Latin American Opportunity Acquisition](https://longbridge.com/en/quote/PLAO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Patria Prepares Next Vintage of Latin America Private Credit Strategy to Capture Structural Scarcity in Corporate Lending \| PAX Stock News | Patria Investments is launching a new vintage of its Latin America private credit strategy, targeting a structurally und | [Link](https://longbridge.com/en/news/275586328.md) |
| Patria Investments Q4 Earnings Report: What Investors Need to Know | Patria Investments (NASDAQ:PAX) reported its Q4 earnings on February 3, 2026, beating estimates by 9% with an EPS of $0. | [Link](https://longbridge.com/en/news/274643328.md) |
| Primrose Hill neighbours in legal battle over wonky basement | Two couples in Primrose Hill are embroiled in a legal dispute over a bulging basement wall, with claims of boundary encr | [Link](https://longbridge.com/en/news/276592124.md) |
| Tyler Technologies, Inc. $TYL Shares Sold by ABN Amro Investment Solutions | ABN Amro Investment Solutions significantly reduced its stake in Tyler Technologies, Inc. by 99.8% in Q3, now holding on | [Link](https://longbridge.com/en/news/276103786.md) |
| Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz) \| LLY Stock News | Eli Lilly's Omvoh (mirikizumab-mrkz) has demonstrated durable efficacy in maintaining steroid-free remission in over 90% | [Link](https://longbridge.com/en/news/276362017.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.